This contention was fully validated by us in mouse breast cancer models [51,52] with two EP4 antagonists (ONO-AE3-208, ONO pharma, Japan; and, RQ-15986, currently renamed as AAT 007, Ask/At Pharma, Japan). Here, PTGER4 is linked to breast cancer.